Pressmeddelanden från H. Lundbeck

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Lundbeck appoints Chief AI Officer 09 mar 10:33

Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial 18 feb 09:32

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 17 feb 10:00

To the shareholders of H. Lundbeck A/S 12 feb 16:39

Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention 06 feb 11:39

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 04 feb 19:13

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 04 feb 07:50

Lundbeck Annual Report 2025 04 feb 07:30

Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026 30 jan 15:00

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference 08 dec 2025 08:22

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 06 dec 2025 18:00

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting 02 dec 2025 08:00

Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting 26 nov 2025 17:23

ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)14 nov 2025 12:44

ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION)14 nov 2025 08:55

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine 11 nov 2025 15:34

Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments 11 nov 2025 15:21

Lundbeck raises financial guidance for 2025 27 okt 2025 09:00

Lundbeck and OpenAI join forces to unlock innovation and boost productivity 20 okt 2025 09:00

Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions 13 okt 2025 08:00

Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies 02 okt 2025 09:00

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 20 sep 2025 08:00

Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD 11 sep 2025 08:00

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine 09 sep 2025 14:30

Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 25 aug 2025 09:00

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy 13 aug 2025 18:40

Guidance raised based on solid H1 results and continued strong expectations for the full year 2025 13 aug 2025 18:34

Lundbeck raises financial guidance for 2025 18 jul 2025 23:24

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)24 jun 2025 08:00

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia 21 jun 2025 13:25

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine 21 jun 2025 13:20

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine 22 maj 2025 17:31

Lundbeck successfully places a EUR 500 million Eurobond 14 maj 2025 07:17

Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER 08 maj 2025 08:00

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston 06 maj 2025 08:00

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer 04 apr 2025 09:00

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting 31 mar 2025 11:00

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention 26 mar 2025 12:28

Lundbeck held its Annual General Meeting on 26 March 2025 at the company’s registered office 13 mar 2025 09:00

Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older 10 mar 2025 09:01

Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan 25 feb 2025 10:00

To the shareholders of H. Lundbeck A/S 21 feb 2025 13:27

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 12 feb 2025 09:00

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA 05 feb 2025 16:40

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties 05 feb 2025 07:46

Lundbeck Annual Report 2024 05 feb 2025 07:23

Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)04 feb 2025 17:10

Lundbeck announces changes to the Board of Directors 30 jan 2025 09:00

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies 09 jan 2025 14:07

Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD 05 dec 2024 13:00

Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations 03 dec 2024 08:00

Efficacy of Vyepti highlighted by new clinical trial results in severe migraine 02 dec 2024 15:08

Lundbeck completes acquisition of Longboard 28 nov 2024 07:56

Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled 27 nov 2024 08:00

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy 13 nov 2024 07:29

Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 31 okt 2024 12:44

Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention 23 okt 2024 09:01

Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth 14 okt 2024 12:30

Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline 03 okt 2024 09:00

Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease 27 sep 2024 14:00

Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders 26 sep 2024 12:00

Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery 20 aug 2024 09:09

Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator 20 aug 2024 08:53

Lundbeck raises financial guidance for 2024 31 jul 2024 08:00

Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S.25 jun 2024 07:59

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)19 jun 2024 08:30

Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial 03 jun 2024 14:00

Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia 15 maj 2024 07:31

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024 13 maj 2024 09:00

Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck 09 apr 2024 08:00

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD 27 mar 2024 08:00

Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia 20 mar 2024 13:33

Lundbeck held its Annual General Meeting on 20 March 2024 at the company’s registered office 15 mar 2024 09:00

Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage 05 mar 2024 09:00

Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders 23 feb 2024 11:00

Notice of Annual General Meeting 23 feb 2024 08:59

Lundbeck announces changes to Executive Management 16 feb 2024 11:45

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 07 feb 2024 15:23

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 07 feb 2024 07:33

Lundbeck Annual Report 2023 07 feb 2024 07:29

Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024 05 feb 2024 15:00

Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck 31 jan 2024 14:06

Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial 29 jan 2024 09:00

Aripiprazole once-every-two-months long-acting injectable recommended for approval in the EU by the CHMP for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole 20 dec 2023 13:27

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 04 dec 2023 12:07

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 30 nov 2023 08:59

Lundbeck R&D Event to showcase innovative pipeline 08 nov 2023 07:30

Lundbeck's revenue in the first nine months of 2023 climbed to DKK 15 billion 14 sep 2023 09:02

Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress 07 sep 2023 10:59

Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults 18 aug 2023 13:21

Lundbeck announces changes to Executive Management 16 aug 2023 07:28

Lundbeck’s revenue increased by 13% (+10% CER) to DKK 10 billion in the first six months of 2023 26 jun 2023 09:33

The Board of Directors initiates CEO succession 16 jun 2023 08:55

Long-term benefits of Vyepti[®] confirmed by new data presented at the annual meeting of the American Headache Society 15 maj 2023 07:53

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties 11 maj 2023 05:25

Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s Disease 10 maj 2023 07:32

Lundbeck’s sales increased by 15% (+11% at constant exchange rates) to DKK 5 billion in the first quarter of 2023 19 apr 2023 15:43

Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention 21 mar 2023 13:27

Lundbeck held its Annual General Meeting on 21 March 2023 at the company’s registered office 22 feb 2023 10:00

Notice of Annual General Meeting